Latest Industry Insights

Patient trust is vital as AI transforms pharma and drug discovery. Discover how transparency and regulation are making innovation safer.

Discover how crowdfunding could help biotech startups and cell and gene therapy developers overcome funding barriers by engaging patients, physicians and everyday investors.

Learn how the Amperia platform improves AAV quantification accuracy and speed, making gene therapy development more accessible and consistent.

Explore the dosing challenges posed by current gene therapies and how circular RNA may unlock more potent and safer therapies.

Families with rare diseases often wait years for answers. GeneDx’s AI-driven dataset, Infinity™, is changing that. In this interview, Dr. Bryan Dechario explains how decades of data are reshaping the future of genomic medicine.

Explore the unique issues of rare disease trials and how “gene silencing” therapies could reshape the future for patients with H-ABC.

ELRIG Drug Discovery 2025 recognizes BubbleFect, a lipid-free cell delivery system that utilizes phase separation peptides for non-viral gene therapy delivery.

Discover how one of the biggest biopharma acquisitions of 2025 aims to expand rare tumor therapies for hard-to-treat cancers like desmoid tumors.

In this article, we explore how AI, robotics and advanced software are transforming biopharma labs, the challenges of adopting these technologies and the vision for the “Lab of the Future.”

In this interview, Dr. Denise Teber, a scientific expert in molecular biology at Charles River Laboratories, discusses how ddPCR is being used to improve contamination risk management.